Team Leader (USP)

PD Dr. Yvonne Genzel
PD Dr. Yvonne Genzel
Phone: +49 391 6110 257
Room: N0.18

Team (USP)

Dipl.-Biol. (t.o.) Thomas Bissinger
Dipl.-Biol. (t.o.) Thomas Bissinger
Phone: +49 391 6110 131
Room: N 0.07
Juliana Coronel, D.Sc.
Juliana Coronel, D.Sc.
Phone: +49 391 6110 256
Room: N0.05
Links: Linkedin
Gwendal Gränicher, M. Sc.
Phone: +49 391 6110 333
Room: N 0.07
Marc Hein, M. Sc
Phone: +49391 6110 236
Room: N 0.6
Alexander Nikolay, M. Sc.
Alexander Nikolay, M. Sc.
Phone: +49 391 6110 226
Room: N0.15
Felipe Tapia
Felipe Tapia
Phone: +49 391 6110 207
Room: N0.15
Yixiao Wu
Phone: 0391 6110 210
Room: N0.15
Claudia Best
Technical Assistant
Phone: +49 391 6110 225
Room: N0.14
Ilona Behrendt
Technical Assistant
Phone: +49 391 6110 222
Room: N0.14
Susanne Koenig
Technical Assistant
Phone: +49 391 6110 223
Room: N0.14
Heike Sperlich
Laboratory Assistant
Phone: +49 391 6110 242
Room: N0.14

Upstream Processing

Header image 1444737340

Upstream Processing

Innovation for modern biotechnological processes will be essential to keep the medical supply affordable for a still increasing world population. New vaccines for pandemics or emerging diseases, therapeutic vaccines, recent developments in gene therapy, and options for cancer treatment (antibody-drug-conjugates), but equally global travelling, global distribution of goods, constant zones of war or terror and aging societies demand for efficient approaches in manufacturing of biologicals to cope with supply needs.

Therefore, ideas for innovative products and new approaches for their production on a small scale have to be transformed into complete process trains at a large scale. Production costs, working volumes, effective scale-up, foot print of plants, product yield, downstream processing and many other issues have to be optimized before a process will be used in pharmaceutical industry. Accordingly, we focus on optimization, intensification and integration of bioprocesses on different levels. These include host cell selection, medium design, cultivation parameters, feeding strategies, dynamics of cell growth and product formation as well as approaches towards efficient high cell density cultures and continuous cultivation. In addition, properties of cell lines, specific aspects of cellular growth and metabolism, virus replication, and recombinant protein expression are characterized in detail.

Currently, we mainly consider production systems for influenza A virus (IAV), modified vaccinia virus Ankara (MVA) virus, and various flaviviruses such as yellow fever virus (YFV), Japanese Encephalitis virus (JEV), and Zika virus (ZIKV). Our focus is on virus particles and viral vectors for vaccination and gene therapy. Therefore, growth and product formation of various adherent as well as suspension host cells are being evaluated.

<i>Vaccinia virus replication cycle. </i> Zoom Image
Vaccinia virus replication cycle.
<em>Influenza virus replication cycle (S. Heldt et al. submitted to PLoS Computational Biology) </em> Zoom Image
Influenza virus replication cycle (S. Heldt et al. submitted to PLoS Computational Biology)
<p><em>Yellow fever virus replication cycle.</em></p> Zoom Image

Yellow fever virus replication cycle.

 
Go to Editor View
loading content